Generic Drugs Market Research Report Information by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, Others), by Route of Administration (Oral, Topical, Parenteral, Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Region (North America, Europe, Asia-Pacific, Rest of the World) - Forecast till 2035

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 Data Mining Process

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 Secondary Research data flow:

3.5 PRIMARY RESEARCH:

3.5.1 Primary Research Data Flow:

3.5.2 Primary Research: Number of Interviews conducted

3.5.3 Primary Research: Regional Coverage

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 Revenue Analysis Approach

3.7 DATA FORECASTING

3.7.1 Data forecasting Type

3.8 DATA MODELING

3.8.1 microeconomic factor analysis:

3.8.2 Data modeling:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 Increasing Incidences of Chronic Diseases across the globe

4.2.2 Rising strategic initiatives by market players

4.2.3 rising demand for affordable medications

4.3 RESTRAINTS

4.3.1 Voluntary product recalls from market players

4.3.2 Brand Loyalty and Doctor Preferences

4.4 OPPORTUNITY

4.4.1 Invesmtent on research & Development (R&D) for generic medicine

4.4.2 Rising Aging Population

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL

5.1.1 Threat of New Entrants

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 Threat of Substitutes

5.1.4 Bargaining Power of Buyers

5.1.5 Intensity of Rivalry

5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET

6 GLOBAL GENERIC DRUGS MARKET, BY INDICATION

6.1 OVERVIEW

6.2 CENTRAL NERVOUS SYSTEM (CNS)

6.3 CARDIOVASCULAR

6.4 UROLOGY

6.5 ONCOLOGY

6.6 RESPIRATORY

6.7 OTHERS

7 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

7.1 OVERVIEW

7.2 ORAL

7.3 TOPICAL

7.4 PARENTERAL

7.5 OTHERS

8 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

8.1 OVERVIEW

8.2 HOSPITAL PHARMACY

8.3 RETAIL PHARMACY

8.4 ONLINE PHARMACY

9 GLOBAL GENERIC DRUGS MARKET, BY REGION

9.1 OVERVIEW

9.2 NORTH AMERICA

9.2.1 US

9.2.2 CANADA

9.3 EUROPE

9.3.1 GERMANY

9.3.2 FRANCE

9.3.3 UK

9.3.4 ITALY

9.3.5 SPAIN

9.3.6 REST OF EUROPE

9.4 ASIA-PACIFIC

9.4.1 China

9.4.2 India

9.4.3 japan

9.4.4 South Korea

9.4.5 AUSTRALIA

9.4.6 Rest of Asia-Pacific

9.5 REST OF THE WORLD

9.5.1 MIDDLE EAST

9.5.2 africa

9.5.3 SOUTH AMERICA

10 COMPETITIVE LANDSCAPE

10.1 INTRODUCTION

10.2 MARKET SHARE ANALYSIS, 2024

10.3 COMPETITOR DASHBOARD

10.4 PUBLIC PLAYERS STOCK SUMMARY

10.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES

10.6.1 PRODUCT LAUNCH

10.6.2 product launch / Product approval

10.6.3 expansion

11 COMPANY PROFILES

11.1 SUN PHARMACEUTICAL INDUSTRIES LTD.

11.1.1 COMPANY OVERVIEW

11.1.2 FINANCIAL OVERVIEW

11.1.3 productS OFFERED

11.1.4 KEY DEVELOPMENTS

11.1.5 SWOT ANALYSIS

11.1.6 KEY STRATEGIES

11.2 LUPIN PHARMACEUTICALS, INC.

11.2.1 COMPANY OVERVIEW

11.2.2 FINANCIAL OVERVIEW

11.2.3 products OFFERED

11.2.4 KEY DEVELOPMENTS

11.2.5 SWOT ANALYSIS

11.2.6 KEY STRATEGIES

11.3 ENDO INTERNATIONAL PLC

11.3.1 COMPANY OVERVIEW

11.3.2 FINANCIAL OVERVIEW

11.3.3 productS OFFERED

11.3.4 KEY DEVELOPMENTS

11.3.5 KEY STRATEGIES

11.4 AUROBINDO PHARMA

11.4.1 COMPANY OVERVIEW

11.4.2 FINANCIAL OVERVIEW

11.4.3 productS OFFERED

11.4.4 KEY DEVELOPMENTS

11.4.5 KEY STRATEGIES

11.5 ASPEN HOLDINGS

11.5.1 COMPANY OVERVIEW

11.5.2 FINANCIAL OVERVIEW

11.5.3 productS OFFERED

11.5.4 KEY DEVELOPMENTS

11.5.5 KEY STRATEGIES

11.6 CIPLA LTD

11.6.1 COMPANY OVERVIEW

11.6.2 FINANCIAL OVERVIEW

11.6.3 PRODUCTS OFFERED

11.6.4 KEY DEVELOPMENTS

11.6.5 SWOT ANALYSIS

11.6.6 KEY STRATEGIES

11.7 NOVARTIS AG

11.7.1 COMPANY OVERVIEW

11.7.2 FINANCIAL OVERVIEW

11.7.3 PRODUCTS OFFERED

11.7.4 KEY DEVELOPMENTS

11.7.5 SWOT ANALYSIS

11.7.6 KEY STRATEGIES

11.8 TEVA PHARMACEUTICAL INDUSTRIES LTD

11.8.1 COMPANY OVERVIEW

11.8.2 FINANCIAL OVERVIEW

11.8.3 productS OFFERED

11.8.4 KEY DEVELOPMENTS

11.8.5 SWOT ANALYSIS

11.8.6 KEY STRATEGIES

11.9 FRESENIUS SE & CO. KGAA

11.9.1 COMPANY OVERVIEW

11.9.2 FINANCIAL OVERVIEW

11.9.3 productS OFFERED

11.9.4 KEY DEVELOPMENTS

11.9.5 KEY STRATEGIES

11.10 VIATRIS INC.

11.10.1 COMPANY OVERVIEW

11.10.2 FINANCIAL OVERVIEW

11.10.3 productS OFFERED

11.10.4 KEY DEVELOPMENTS

11.10.5 KEY STRATEGIES

12 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT

TABLE 2 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 3 GLOBAL GENERIC DRUGS MARKET, FOR CENTRAL NERVOUS SYSTEM (CNS), BY REGION, 2019–2035 (USD BILLION)

TABLE 4 GLOBAL GENERIC DRUGS MARKET, FOR CARDIOVASCULAR, BY REGION, 2019–2035 (USD BILLION)

TABLE 5 GLOBAL GENERIC DRUGS MARKET, FOR UROLOGY, BY REGION, 2019–2035 (USD BILLION)

TABLE 6 GLOBAL GENERIC DRUGS MARKET, FOR ONCOLOGY, BY REGION, 2019–2035 (USD BILLION)

TABLE 7 GLOBAL GENERIC DRUGS MARKET, FOR RESPIRATORY, BY REGION, 2019–2035 (USD BILLION)

TABLE 8 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)

TABLE 9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 10 GLOBAL GENERIC DRUGS MARKET, FOR ORAL, BY REGION, 2019–2035 (USD BILLION)

TABLE 11 GLOBAL GENERIC DRUGS MARKET, FOR TOPICAL, BY REGION, 2019–2035 (USD BILLION)

TABLE 12 GLOBAL GENERIC DRUGS MARKET, FOR PARENTERAL, BY REGION, 2019–2035 (USD BILLION)

TABLE 13 GLOBAL GENERIC DRUGS MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)

TABLE 14 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 15 GLOBAL GENERIC DRUGS MARKET, FOR HOSPITAL PHARMACY, BY REGION, 2019–2035 (USD BILLION)

TABLE 16 GLOBAL GENERIC DRUGS MARKET, FOR RETAIL PHARMACY, BY REGION, 2019–2035 (USD BILLION)

TABLE 17 GLOBAL GENERIC DRUGS MARKET, FOR ONLINE PHARMACY, BY REGION, 2019–2035 (USD BILLION)

TABLE 18 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019–2035 (USD BILLION)

TABLE 19 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION)

TABLE 20 NORTH AMERICA GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 21 NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 22 NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 23 US GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 24 US GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 25 US GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 26 CANADA GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 27 CANADA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 28 CANADA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 29 EUROPE: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION)

TABLE 30 EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 31 EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 32 EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 33 GERMANY: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 34 GERMANY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 35 GERMANY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 36 FRANCE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 37 FRANCE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 38 FRANCE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 39 UK: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 40 UK: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 41 UK: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 42 ITALY: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 43 ITALY: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 44 ITALY: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 45 SPAIN: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 46 SPAIN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 47 SPAIN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 48 REST OF EUROPE: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 49 REST OF EUROPE: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 50 REST OF EUROPE: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 51 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION)

TABLE 52 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 53 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 54 ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 55 CHINA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 56 CHINA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 57 CHINA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 58 INDIA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 59 INDIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 60 INDIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 61 JAPAN: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 62 JAPAN: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 63 JAPAN: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 64 SOUTH KOREA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 65 SOUTH KOREA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 66 SOUTH KOREA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 67 AUSTRALIA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 68 AUSTRALIA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 69 AUSTRALIA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 70 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 71 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 72 REST OF ASIA-PACIFIC: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 73 REST OF THE WORLD: GENERIC DRUGS MARKET, BY COUNTRY, 2019–2035 (USD BILLION)

TABLE 74 REST OF THE WORLD: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 75 REST OF THE WORLD: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 76 REST OF THE WORLD: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 77 MIDDLE EAST: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 78 MIDDLE EAST: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 79 MIDDLE EAST: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 80 AFRICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 81 AFRICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 82 AFRICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 83 SOUTH AMERICA: GENERIC DRUGS MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 84 SOUTH AMERICA: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 85 SOUTH AMERICA: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 86 PUBLIC PLAYERS STOCK SUMMARY

TABLE 87 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL

TABLE 88 PRODUCT LAUNCH

TABLE 89 PRODUCT LAUNCH/ PRODUCT APPROVAL

TABLE 90 EXPANSION

TABLE 91 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED

TABLE 92 SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY DEVELOPMENTS

TABLE 93 LUPIN PHARMACEUTICALS, INC.: PRODUCT OFFERED

TABLE 94 LUPIN PHARMACEUTICALS, INC.: KEY DEVELOPMENTS

TABLE 95 ENDO INTERNATIONAL PLC: PRODUCT OFFERED

TABLE 96 ENDO INTERNATIONAL PLC: KEY DEVELOPMENTS

TABLE 97 AUROBINDO PHARMA: PRODUCT OFFERED

TABLE 98 AUROBINDO PHARMA: KEY DEVELOPMENTS

TABLE 99 ASPEN HOLDINGS: PRODUCT OFFERED

TABLE 100 CIPLA LTD.: PRODUCTS OFFERED

TABLE 101 CIPLA LTD.: KEY DEVELOPMENTS

TABLE 102 NOVARTIS AG: PRODUCTS OFFERED

TABLE 103 NOVARTIS AG: KEY DEVELOPMENTS

TABLE 104 TEVA PHARMACEUTICAL INDUSTRIES LTD: PRODUCT OFFERED

TABLE 105 TEVA PHARMACEUTICAL INDUSTRIES LTD: KEY DEVELOPMENTS

TABLE 106 FRESENIUS SE & CO. KGAA: PRODUCT OFFERED

TABLE 107 FRESENIUS SE & CO. KGAA: KEY DEVELOPMENTS

TABLE 108 VIATRIS INC.: PRODUCT OFFERED

TABLE 109 VIATRIS INC.: KEY DEVELOPMENTS
 

LIST OF FIGURES

FIGURE 1 GLOBAL GENERIC DRUGS MARKET: STRUCTURE

FIGURE 2 GLOBAL GENERIC DRUGS MARKET: MARKET GROWTH FACTOR ANALYSIS (2024-2035)

FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)

FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL GENERIC DRUGS MARKET

FIGURE 6 GLOBAL GENERIC DRUGS MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)

FIGURE 7 GLOBAL GENERIC DRUGS MARKET, BY INDICATION, 2024 & 2035 (USD BILLION)

FIGURE 8 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY INDICATION, 2024

FIGURE 9 GLOBAL GENERIC DRUGS MARKET, ROUTE OF ADMINISTRATION SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)

FIGURE 10 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2024 & 2035 (USD BILLION)

FIGURE 11 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY ROUTE OF ADMINISTRATION, 2024

FIGURE 12 GLOBAL GENERIC DRUGS MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2019-2035 (USD BILLION)

FIGURE 13 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2024 & 2035 (USD BILLION)

FIGURE 14 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2024

FIGURE 15 GLOBAL GENERIC DRUGS MARKET, BY REGION, 2019 & 2035 (USD BILLION)

FIGURE 16 GLOBAL GENERIC DRUGS MARKET SHARE (%), BY REGION, 2024

FIGURE 17 NORTH AMERICA MARKET ANALYSIS: GENERIC DRUGS MARKET, 2019-2035 (USD BILLION)

FIGURE 18 NORTH AMERICA: GENERIC DRUGS MARKET, BY COUNTRY, 2024 & 2035 (USD BILLION)

FIGURE 19 NORTH AMERICA: GENERIC DRUGS MARKET SHARE (%), BY COUNTRY, 2024

FIGURE 20 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)

FIGURE 21 EUROPE: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)

FIGURE 22 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)

FIGURE 23 ASIA-PACIFIC: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)

FIGURE 24 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 & 2035 (USD BILLION)

FIGURE 25 REST OF THE WORLD: GENERIC DRUGS MARKET SHARE, BY COUNTRY, 2024 (%)

FIGURE 26 GENERIC DRUGS MARKET PLAYERS: COMPETITIVE ANALSIS, 2024

FIGURE 27 COMPETITOR DASHBOARD: GLOBAL GENERIC DRUGS MARKET

FIGURE 28 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 29 SUN PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 30 LUPIN PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 31 LUPIN PHARMACEUTICALS, INC.: SWOT ANALYSIS

FIGURE 32 ENDO INTERNATIONAL PLC: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 33 AUROBINDO PHARMA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 34 ASPEN HOLDINGS: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 CIPLA LTD.: FINANCIAL OVERVIEW

FIGURE 36 CIPLA LTD.: SWOT ANALYSIS

FIGURE 37 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 38 NOVARTIS AG: SWOT ANALYSIS

FIGURE 39 TEVA PHARMACEUTICAL INDUSTRIES LTD: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 40 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS

FIGURE 41 FRESENIUS SE & CO. KGAA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 42 VIATRIS INC.: FINANCIAL OVERVIEW SNAPSHOT